Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment
Thomas Morel(UCB Pharma (Belgium)), Karlin Schroeder(Novartis (United States)), William S. Brooks(University of Alabama at Birmingham), Carroll Siu(Parkinson's UK), Ashley F. Slagle, Stefan Cano(Health Economics and Outcomes Research (United Kingdom)), Kate Trenam(UCB Pharma (Belgium)), Natasha Ratcliffe(Parkinson's UK), Casey Gallagher(Parkinson's Foundation), Paul Burns(University of Mississippi Medical Center), Lesley Gosden(Parkinson's UK), Roger A. Barker(University of Cambridge), Babak Boroojerdi(UCB Pharma (Germany)), John Andrejack(Parkinson's Foundation), Geraldine Blavat(Parkinson's Foundation), Sophie Cleanthous
Cited by 45
Related Papers
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
|New England Journal of Medicine|2015|6k
Cells of the human intestinal tract mapped across space and time
|Nature|2021|712
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations
|The Lancet Neurology|2007|497